1 July 2024

Relevant security:	Ordinary shares in RADIOPHARM THERANOSTICS LTD	
Identity of the taker:	Point72 Associates, LLC	
	rm Theranostics Ltd releasing the information contained in this formal disciplination to us once this has been released to the ASX.	closure
may give rise to unacceptable	the non-disclosure of long positions, including long equity derivative positions circumstances. Point72 Asset Management, L.P. ( <b>Point72</b> ), as investment <b>Fund</b> ), discloses the below information on behalf of the Fund, as at the d	manager
	: Equity Derivatives (GN20) issued by the Australian Takeovers Panel. Term meaning given to them in GN20.	ns not
Equity Derivatives of Point72 Associates, LLC in Radiopharm Theranostics Ltd		
Dear Mr Hains,		
Australia		
Carlton South VIC 3053		
Level 3, 62 Lygon Street		
c/- The CFO Solution		
Company Secretary		
Mr Phillip Hains		



Price (including reference price, strike price, option price etc as appropriate):	Not applicable.
Entry date and number of securities to which the derivative relates:	Total number of securities to which derivatives relate as at 1 July 2024: [54,029,156 ORDs]
Type of derivative (e.g. contract for difference, cash settled put or call option):	Cash settled equity swap
Any material changes to information previously disclosed to the market:	No information previously disclosed
Relevant interest in the securities:	None
Long equity derivative positions held by the taker and its associates:	The Fund has no other associates with a long equity derivative position or relevant interest in the company
Short equity derivative positions that offset long positions	None
Short positions of more than 1% that have been acquired after a long position is disclosed, whether by notice or substantial holding notice.	None

Yours sincerely,

Vincent Tortorella

General Counsel and Chief Compliance Officer

Point72 Asset Management, L.P.